- Sartorius and MAbSilico are collaborating to connect AI-driven protein discovery with automated, high-throughput cell line development - The integrated workflow enables computational developability assessment and stable pool screening of up to 200 variants and expression conditions in 12 weeks - This combined service links sequence design to high-yield production cell lines, shortening timelines and reducing manufacturing risks
Göttingen, Germany | Tours, France | September 28, 2026
Sartorius and France-based MAbSilico have entered a non-exclusive collaboration combining AI-powered predictive algorithms from MAbSilico with cell line development (CLD) capabilities from Sartorius. Together, they offer an integrated service to assess the developability and manufacturability of therapeutic candidates from sequence design to robust and proven expression systems.
With this comprehensive solution, clients will be able to evaluate biophysical and developability profiles in silico before wet-lab screening and validations. This helps identify and eliminate candidates with liabilities such as post-translational modification hotspots, aggregation propensity, and weak target binding that can emerge in later development stages.
The workflow enables early assessment of a large number of sequence variants and generates representative material for evaluating cell growth, titer, and product quality. By accounting for genetic and epigenetic factors through stable integration in a CHO host, it supports a smoother transition toward investigational new drug (IND) submission while reducing development timelines, scalability challenges, and operational risk.
"We are happy and proud to partner with Sartorius, one of the major players in drug development, and to be able to share our AI-based technologies directly with their global client network," said Vincent Puard, Chief Executive Officer of MAbSilico. "By deploying our services within the standard-setting bioprocessing ecosystem offered by Sartorius, we’re empowering biotech and pharmaceutical companies to speed up the design and engineering of high-potential lead candidates and support successful cell line development using an established platform with a strong regulatory track record. This collaboration represents a natural step in our mission to turn antibody discovery into a predictive, high-velocity engine."
“Through the collaboration with MAbSilico, Sartorius is expanding its support for biopharmaceutical developers at the lead optimization stage,” said Vanessa Lutz, Head of Cell Line Development at Sartorius. “By combining AI-driven prediction with high-throughput experimental validation, we can identify the most promising candidates earlier, reduce development risk, and help clients reach IND faster.”
More information about CHO CLD Services:
Cell Line Development Services | Sartorius
A profile of Sartorius
Sartorius is a leading international partner to life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies more safely, rapidly, and sustainably. Based in Göttingen, Germany, the company has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2025, the company generated sales revenue of around 3.4 billion euros. More than 14,000 employees work for customers around the globe.
Visit our Newsroom or follow us on LinkedIn.
A profile of MAbSilico
Based in Tours, France, MAbSilico is a pioneer TechBio company dedicated to developing and providing cutting-edge AI-based solutions for antibody drug design and discovery. Based on the most advanced curated antibody database, MAbSilico developed AI-solutions for antibody design and engineering by combining 3D modeling, complex interaction simulations, and advanced linear sequence analysis. MAbSilico empowers biotech and pharmaceutical companies to significantly mitigate antibody discovery risks by providing high-potential computational candidates in just a matter of days.
For more information, visit www.mabsilico.com
Contact Sartorius
Dan Stanton
Trade Media Relations Expert
Dan.stanton@sartorius.com
Contact MAbSilico
Vincent Puard
CEO and co-founder
vincent.puard@mabsilico.com
+33 769 860 902